Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | HBB | P68871 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.58 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL1829348 | 0.91 | ALDH1A1 (0.49) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL1176577 | 0.87 | PNP (0.62) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL3701 | 0.87 | PNP (0.62) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL27871419 | 0.86 | PNP (0.61) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL28189108 | 0.86 | PNP (0.61) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL27833745 | 0.86 | PNP (0.61) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL28385604 | 0.86 | PNP (0.61) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL11551819 | 0.84 | PNP (0.45) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL28849539 | 0.83 | PNP (0.57) | ALDH1A1HPGDHBBTP53PTGS1 | |
| Thioguanine SCHEMBL27820845 | 0.81 | ALDH1A1 (0.87) | ALDH1A1HPGDHBBTP53PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2918589-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2016-11-02 | — | — | EP | claimed |
| EP-2918589-A1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | Intellikine, LLC (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2456444-B1 | ADENINE DERIVATIVE AS PI3K INHIBITOR | INTELLIKINE LLC (US) | 2015-03-18 | — | — | EP | claimed |
| EP-0105404-A1 | Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation | MERCK & CO. INC. (US) | 1984-04-18 | — | — | EP | claimed |
| US-20240141030-A1 | VEGF-BINDING MOLECULES | BOEHRINGER INGELHEIM INT (DE) | 2024-05-02 | — | — | US | disclosed |
| US-20240124581-A1 | ANTIBODY MOLECULES FOR CANCER TREATMENT | BOEHRINGER INGELHEIM INT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-112584824-B | Nanoparticles | 新泰福托特股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11795219-B2 | Antibody molecules for cancer treatment | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| WO-2023146866-A2 | METHODS FOR TREATING CALCITONIN GENE-RELATED PEPTIDE (CGRP) - EXPRESSING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230203146-A1 | ANG2-BINDING MOLECULES | BOEHRINGER INGELHEIM INT (DE) | 2023-06-29 | — | — | US | disclosed |
| CN-116209439-A | Substituted N- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) arylsulfonamide analogs as cereblon modulators | 圣裘德儿童研究医院有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11312785-B2 | Antagonizing CD73 antibody | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-1255753-A2 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | Gemin X Biotechnologies Inc. (CA) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055131-A2 | PRODIGIOSIN-DERIVATIVES AS NEOPLASTIC AND ANTI-VIRAL AGENTS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2001-08-02 | — | — | WO | disclosed |
| WO-2000066767-A1 | ESTROGEN SIGNALLING PATHWAY REGULATORS AND USES THEREOF | NORTH SHORE LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6039684-A | Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome | ALLEGHENY UNIVERSITY OF THE HEALTH SCIENCES (US) | 2000-03-21 | — | — | US | disclosed |
| US-5876692-A | TO PREVENT HOST REJECTION RESPONSES. | THE UNIVERSITY OF PITTSBURGH (US) | 1999-03-02 | — | — | US | disclosed |
| US-5854231-A | Pharmaceutical composition for inhibiting the growth of cancers | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-29 | — | — | US | disclosed |
| US-5635156-A | SUBJECTING RECIPIENT TO TREATMENT WITH NON-LETHAL DOSE OF TOTAL BODY IRRADIATION, ALKYLATING AGENT, ANTIBODY OR ACTIVE FRAGMENT THEREOF, TRANSPLANTING WITH DONOR CELL PREPARATION CONTAINING HEMATOPOIETIC STEM CELLS | UNIVERSITY OF PITTSBURGH (US) | 1997-06-03 | — | — | US | disclosed |
| US-5514364-A | Non-lethal methods for conditioning a recipient for bone marrow transplantation | UNIVERSITY OF PITTSBURGH (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240141030-A1 | VEGF-BINDING MOLECULES | VEGFA, KDR, FLT1 | ALDH1A1 3195/4885HPGD 3272/4885HBB 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.